Dymedso Inc. entered into an agreement in principle to acquire Bold Capital Enterprises Ltd. (TSXV:BOLD.P) in a reverse merger transaction on April 28, 2020. Upon the closing of the acquisition, the shareholders of Bold and Dymedso will hold respectively 12% and 88% of all the issued and outstanding common shares of Bold, calculated prior to any additional financing. Subject to applicable approvals, it is anticipated that four out of the five Directors of Dymedso to be nominated will be Richard Boudreault, Kim Anderson, Simon Phaneuf and Yvon Robert. Management of Dymedso will include Kim Anderson as President, Richard Boudreault as Chief Executive Officer and Chairman of the Board, and Simon Phaneuf as Chief Scientific Officer. The qualifying transaction constitutes an arm’s length qualifying transaction. The qualifying transaction is subject to various conditions such as its approval by the board of directors of Bold and Dymedso, the hiring of a brokerage firm, the completion of a concurrent private or public placement of a minimum of CAD 2 million and a maximum of CAD 5 million, Exchange acceptance and if applicable pursuant to exchange requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. The transaction is not subject to shareholder approval. The Board of Directors of Bold Capital Enterprises Ltd. approved on June 18, 2020, a resolution pertaining to the implementation of the “Bold Capital Enterprises Ltd. 2020 Stock Option Plan”, conditional to the completion of a proposed qualifying transaction. Bold Capital Enterprises will hold a special meeting of shareholders on July 24, 2020, to amend the articles of the corporation to effect the change of its name to “Dymedso Inc.”, or such other name as the Board may determine, conditional to the completion of the proposed qualifying transaction. The articles of Bold Capital might also be amended to effect a consolidation of all shares of Bold Capital, on the basis of a maximum consolidation ratio of four pre-consolidation common share to one post-consolidation common share. On October 16, 2020, Bold Capital and Dymedso extended to December 15, 2020, the expiring of this agreement in principle.